











Page 1 of 40 Laryngoscope Investigative Otolaryngology
This is the author manuscript accepted for publication and has undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process, which may lead to differences
between this version and the Version of record. Please cite this article as doi:10.1002/lio2.178.











Is there a difference in staging and treatment of head and neck 
squamous cell tumors between tertiary care and community-based 
institutions? 
 
Short title: Institutional cancer staging differences 
 
 
Sarah R. Akkina, MD, MS1,2; Roderick Y. Kim, DDS, MD1,3, Chaz L. Stucken, MD4, Melissa A. Pynnonen, 
MD, MS4, Carol R. Bradford, MD4 
 
1 University of Michigan Medical School, Ann Arbor, MI 
2 Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, WA  
3 Department of Surgery, Section of Oral and Maxillofacial Surgery, University of Michigan Health 
System, Ann Arbor, MI  
4 Department of Otolaryngology-Head and Neck Surgery, University of Michigan Health System, Ann 
Arbor, MI 
 
This study was supported by the University of Michigan Head and Neck Cancer SPORE (NCI P50 
CA97248) and the University of Michigan Comprehensive Cancer Center Core Grant (NCI P30 
CA46592). The authors have no other funding, financial relationships, or conflicts of interest to 
disclose. The content is solely the responsibility of the authors and does not necessarily represent 
the official views of the National Institutes of Health. 
 
This study was presented at the Combined American Head and Neck Society Section Meetings, 
Boston, Massachusetts, April 24, 2015.  
 
Acknowledgements: We would like to acknowledge the UM HN-SPORE team and particularly Lisa 
Peterson for her management of the database and assistance with data coding.  
 
Corresponding author:  
Chaz L. Stucken, MD, Assistant Professor 
Department of Otolaryngology-Head and Neck Surgery 
University of Michigan 
1904 Taubman Center 
1500 E. Medical Center Drive 
Ann Arbor, MI 48109-5312 
Email:  cstucken@med.umich.edu 
Phone: (734) 936-8051 
Fax: (734) 936-9625 
 
Page 2 of 40Laryngoscope Investigative Otolaryngology












Objective: To characterize the differences in the staging and treatment of patients with head and 
neck squamous cell carcinoma between a tertiary care center and community-based practices. 
Methods: This study is a retrospective chart review of 943 adult patients with head and neck 
squamous cell cancer presenting to a tertiary care center between 2008 and 2014 as part of the 
University of Michigan Head and Neck Cancer Specialized Program of Research Excellence (UM HN-
SPORE) database. Demographic information, diagnostic testing, staging information, and treatment 
recommendations were recorded.  
Results: Of 943 patients reviewed, 159 had documentation of tumor stage that was assigned by the 
community-based practice. Of these, 53% had a tumor staging change made at the tertiary care 
center, with 43% of patients upstaged and 10% of patients downstaged. 51% received different 
treatment than had previously been offered at the community-based practice, although only 31% of 
these patients had a change in tumor staging.  
Conclusion: Over half of patients with head and neck squamous cell carcinoma who are evaluated 
at a tertiary care center after the initial evaluation at a community-based practice have their tumors 
staged differently, with the majority upstaged. A significant number of these patients also received 
different treatment than was initially offered at the referring practice. Future studies are required 
to determine whether these differences have an effect on tumor recurrence and patient survival 
rates.  
 
Key Words: adult head and neck squamous cell carcinoma, neoplasm staging, tertiary care 
center 
 
Level of Evidence: 2c (Outcomes Research) 
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In the assessment of head and neck cancer, accurate staging is imperative because 
prognosis and treatment are directly related to the tumor stage assigned to each patient.1 Tumor 
staging allows meaningful discussion between members of the patient care team to achieve an 
appropriate and customized treatment plan for each patient.2,3 Originating from the American Joint 
Committee on Cancer (AJCC) in conjunction with the International Union Against Cancer (UICC), 
TNM classification of head and neck cancer4 is now the standard staging system used in clinical 
practice and the published literature.1  
Despite the importance of initial staging, relatively few studies have examined differences in 
the staging process or compared tumor stage assignments between institutions. Although studies 
have shown a disparity in survival rates of head and neck cancer patients between different 
institutions, no study has compared tumor staging assignments to identify staging differences and 
restaging between institutions.5,6  
We hypothesized that there are institutional differences in tumor stage assignment. We 
sought to quantify these differences and to identify patient-specific factors associated with these 
differences and secondarily to compare differences in treatment recommendations.  We designed a 
study to compare institutional tumor staging by examining patients diagnosed with head and neck 
squamous cell carcinoma at community-based practices who subsequently presented to our 
tertiary care academic center. We sought to identify whether staging differences identified are a 
result of patient-specific factors, if different treatment was offered at the tertiary care center, and if 
treatment differences were related to staging changes. 
 
Materials and Methods 
A retrospective chart review was conducted on patients within the University of Michigan 
Head and Neck Cancer Specialized Program of Research Excellence (UM HN-SPORE).  The UM HN-
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SPORE database consists of patients who have presented to the University of Michigan for 
evaluation and treatment of head and neck cancers, and consented to be in research studies 
regarding factors impacting treatment and survival of their cancers.  We identified patients who 
had previously been staged at a community-based practice and had subsequently been staged at 
our tertiary care center, the University of Michigan. We included all patients with HNSCC. Upon 
registration into the UM HN-SPORE database, demographic information on each patient had been 
collected along with diagnosis, treatment, and outcome measures. Race was self-reported by 
patients. For the purposes of this study, the data collection also included chart review of referral 
documentation to determine tumor staging by community-based practice, treatment offered by the 
community practice, and whether the patient then presented to the tertiary care center for 
assumption of care versus a second opinion. Descriptive statistics were calculated on 
demographics, changes in staging, reasons for changes in stage, and treatment offered. 
Demographic differences were analyzed between patients with staging changes, compared to those 
with no staging change, using Fisher’s Exact test at a significance level of alpha = 0.05.   Statistical 




In total, 943 patients were reviewed. Of these, 159 patients had complete documentation 
from the community-based practice including tumor staging; this patient subset was the main 
group analyzed. The mean age of these patients was 60 years. 77% of patients were male, 23% 
female, and the vast majority were European American/White (91%) with the remainder including 
6% African American/Black, 1% Asian, 2% American Indian/Eskimo/ Aleutian, and 1% other.   
Wait-time between staging of patient at the community-based practice and initial presentation to 
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the tertiary care center was on average 14.7 days. Complete patient characteristics and tumor sites 
and stages as determined by the tertiary care center are demonstrated in Table 1 and 2. 
Following evaluation at the tertiary care center, 85 (53%) patients were re-assigned a 
different tumor stage, with 69 (43%) patients upstaged and 16 (10%) patients downstaged [Table 
3]. Of the patients with staging changes, 45 (53%) had been evaluated by a multidisciplinary tumor 
board at the tertiary care institute. Of this subset, 24 patients underwent stage change based on the 
tumor board recommendations, with the other 21 patients having had an initial staging that was 
already changed from that given at the referring institute during tertiary care clinic evaluation. 
Patients with HNSCC of the oropharynx and of the tongue were most commonly upstaged compared 
to other tumor sites [Figure 1]. Reasons for staging changes included differences in clinical exam at 
the tertiary care center (e.g. lymph node determined to be larger), differences in radiology reviews 
(e.g. an additional enlarged lymph node identified), and new imaging taken. Patient characteristics 
including demographics, disease recurrence, and persistence were compared between those that 
had tumor staging changes made at the tertiary care center and those that did not. Fisher Exact 
testing, between patients with tumor staging change and those without, did not reveal any 
statistically significant differences [Table 4].  
Treatment offered at the community-based practice was then compared to treatment 
received by the patient at the tertiary care center. Of the 159 patients with outside records 
analyzed, 78 patients had documentation of specific treatment recommendations at the 
community-based practice and treatment received at the tertiary care center. Of these, 37 (47%) 
patients received treatment that was different than what was recommended by the community-
based practice. Interestingly, only 18 of these patients, or roughly half, had staging changes made. 
Thus, 19 patients received treatment that was different than initially recommended by the 
community-based practice even without having undergone a change in tumor staging status. Also of 
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note, of the 37 patients with a treatment change, 20 (54%) had been referred for a second opinion, 
not specifically for assumption of clinical care.  
 
Discussion 
Tumors of the head and neck are expected to be clinically staged under AJCC guidelines,1 
but our data reveals that HNSCC tumors are often staged differently at tertiary care centers 
compared to community-based practices. In patients analyzed in this study, over half of tumors 
were restaged. The majority were restaged with a more advanced stage by the tertiary care center, 
despite relatively minimal time between the referral and tertiary care center evaluation. 
Additionally, many of the patients had a change in treatment received at the tertiary care center 
compared to what was recommended by the community-based practice. Roughly half of these 
patients had their tumor staging changed prior to treatment. The other half did not, meaning the 
change in treatment recommended was due to a factor outside of tumor staging. Details of why 
each patient’s treatment regimen was recommended at the community-based hospital were unable 
to be characterized, though presumably related to evaluation of clinical characteristics and 
imaging/diagnostic studies.  
The differences in tumor staging between community-based practices and tertiary care 
centers may be attributed to overall volume and experience with head and neck cancer, as well as 
the availability of additional specialists including highly trained radiologists and cytopathologists 
available through multidisciplinary tumor boards to clarify clinically challenging cases. Previous 
literature has examined overall differences in survival of head and neck cancer patients at different 
treating institutions.5,6 One such study evaluating patients with local advanced head and neck 
cancer undergoing definitive radiotherapy found that treatment at high-volume facilities and 
academic centers is independently associated with improved survival, using the National Cancer 
Data Base to include over 46,000 patients.7 When determining what led to the difference, studies 
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have implicated factors such as the volume of treatments rendered at the facilities8, technical 
expertise 9 as well as multidisciplinary team management 3,9. In one study examining 1195 
Medicare patients with advanced head and neck cancer treated at high and low volume centers, 
patients were found to have nearly statistically significant better survival at high volume hospitals 
despite no association found in receiving multimodality therapy.10 This implies that survival-
promoting features of high volume hospitals extends beyond guideline adherence. These studies 
overall also imply a difference in overall patient care across institutions and may explain the 
observed negative effect on survival noted on the literature.3,6 Therefore, it is apparent that further 
exploration of the staging process represents a major avenue for identifying factors that affect the 
institutional-based outcome differences.  
 A typical diagnostic work-up to determine staging traditionally involves a thorough history 
and physical examination, followed by additional testing which may include endoscopy of the upper 
aerodigestive tract, imaging via computed tomography (CT), magnetic resonance imaging (MRI), 
ultrasonography (US), fine needle aspiration cytology (FNAC) of a neck mass and incisional biopsy 
of the primary tumor 11-13. While these additional tests can lead to greater accuracy in determining 
disease extent, clinical judgment of the practitioner or general institutional guidelines may 
conclude that additional testing is unnecessary to accurately stage the tumor. Therefore, a wide 
range of test utilization between practitioners and institutions is likely. Recently, Lewis et al have 
analyzed pre-referral staging at community institutions for adherence to the National 
Comprehensive Cancer Network (NCCN) guidelines. Their data showed significant deviation from 
the guidelines by community-based practices, leading to inadequate surgical treatment and 
misdiagnosis for patients treated only at community institutions 14.  
At our tertiary care center, staging is based on NCCN guidelines and is often confirmed or 
augmented via evaluation by a multidisciplinary tumor board. In this dataset, of 159 patients 
identified, 84 (53%) underwent tumor board evaluation. Community-based practices often do not 
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have such easy and coordinated access to specialists of other disciplines which can significantly aid 
in the evaluation of tumors, especially in more complicated cases or areas of tumor that are more 
rare, therefore very infrequently seen in the community. The positive effect of multidisciplinary 
tumor boards in impacting patient assessment and management has been studied in many 
oncological settings, from head and neck cancer to breast, urologic, gastrointestinal, and 
gynecological cancers.15-20 A recent systematic review reporting that between 4% to 45% of 
patients discussed at multidisciplinary team meetings had changes in diagnostic reports.21 
Additionally, the clinical impact of multidisciplinary head and neck tumor board has been 
previously studied, examining discussion of 120 consecutive patients which revealed that 27% of 
patients had some change in tumor diagnosis, stage, or treatment plan.15 Our study has gone a step 
further in directly assessing the referral documentation and work up at community-based 
practices, as well as patient demographic factors. Our findings support the prior study’s conclusion 
that multidisciplinary approaches to patient care affect staging and treatment recommendations. 
Regarding staging, our data reveals that particular tumor sites may lead to increased 
staging discrepancies, as 68% of oropharynx tumors were re-staged at the tertiary care center 
compared to 49% of oral cavity tumors and 41% of larynx tumors. This may relate to the changes in 
oropharynx tumor staging with the important recognition of differences in survival for Human 
Papilloma Virus (HPV)-associated tumors.22 As new staging systems have arisen, academic centers 
may have earlier access to this information and process than community-based centers. 
Additionally, oropharyngeal tumors can be difficult to assess radiologically in regards to 
involvement in extrinsic musculature of the tongue or pterygoids which highly trained radiologists 
can aid with at academic centers particularly through multidisciplinary tumor boards. Community-
based centers may not have the same access. With classification of HPV tumors, cytopathology also 
plays a crucial role. Academic centers may have better access to more specialized cytopathologists 
as well. The interpretation of diagnostic studies is subject to high variability between institutions 
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and between providers, possibly leading to the deviations.  Previous studies have indicated that 
reinterpretation of imaging in the setting of a multidisciplinary cancer center has a significant effect 
on staging, management, and prognosis9,23,24. As our data shows, roughly half of the patients 
evaluated with staging changes had this change made in the context of review by a 
multidisciplinary tumor board.  
There are several limitations of this study. First, the database was limited to patients who 
sought evaluation at a tertiary care center.  This group may inherently be more difficult to examine 
and diagnose, leading to greater discrepancy in staging. Additionally, referral documents used in 
chart review may not have included all outside clinical notes which community-based practices 
may have used to determine tumor stage.  The patient group was fairly diverse with respect to 
tumor site and stage, making it difficult to identify any differences in outcome or whether 
differences in patient characteristics could be confounding. It is also possible that patients may not 
have been clinically understaged, but rather that the disease progressed by the time they were 
referred to our institution. However, given our finding that patients were subsequently evaluated at 
the tertiary care center on average only 14 days after their referral encounter, this is less likely to 
present a significant limitation. Additionally, it could be argued that because this study is limited to 
patients presenting to a tertiary care center, that community-based practices may not have 
conducted additional tests or diagnostic studies out of an assumption that the tertiary care center 
would assume care and give a final stage and recommendation. However, as noted above, among 
the group of patients with changes in treatment recommendations, 54% had presented for a second 
opinion, without which they presumably would have underwent the initial treatment offered by the 
referring institution. Finally, there is an underlying assumption that the tertiary care center was 
fully adherent to NCCN guidelines in staging; this study did not officially validate the tertiary care 
center staging concordance with NCCN guidelines, and discrepancies therefore could exist.  
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Future studies should examine the differences in exactly how community-based practices 
versus tertiary institutions stage patients, specifically focusing on the tests ordered at each 
institution to aid with staging. Ultimately, survival based on the changes in staging and treatment 
modalities offered to patients at different institutions should be examined in order to determine 
overall and disease free survival. 
 
Conclusion  
Over half of patients with HNSCC who present to tertiary care centers from community-
based practices have their tumors’ stage changed, with the majority upstaged. Interestingly, in 
nearly half of patients receiving treatment that is different than was initially recommended at the 
community-based practice; only half of these patients had undergone a tumor staging change. 
Future studies are required to determine whether these differences result in an effect on patient 
outcomes, including recurrence and survival rates. 
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Table 1. Patient Demographics  
 
Patient Characteristics 
Percent of total  
(N = 159) 
Sex  
    Male 77 
    Female 23 
Age (Years) 60 
Race  
European American/White 91 
African American/Black 6 
Asian 1 
American Indian/Eskimo/Aleutian  2 
Other  1 
Baseline tobacco status  
Never smoker  25 
Current in past 12 mo 47 
Former smoker >12mo  28 
Baseline alcohol status  
Never drinker  8 
Current drinker  69 
Former drinker >12mo 23 
BMI Category  
Underweight  7 
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t  327 
 328 
329 
Normal  40 
Overweight  32 
Obese 21 
Recurrence  
Alive, no recurrence 77 
Recurred or persistence  23 
Disease Persistence  
No disease present after treatment  88 
Disease present after treatment 
completed or palliative at baseline  
12 
Education Level (N = 121) 
Less than High School  6 
High School or GED  30 
Some College  37 
4 year degree or greater  27 
Marital Status (N = 155) 
Married  67 
Widowed  10 
Separated or divorced  8 
Never married  14 
Median Household Income ($) 48,202.00 
Average Wait Time 14.7 days  
(Range 0-163 days) 
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Table 2. Patient tumor sites and stages determined by tertiary care center 
 
Tumor Site Stage 1 Stage 2 Stage 3 Stage 4 Total 
Larynx 10 4 4 14 32 
Oral cavity  7 11 8 27 53 
Oropharynx  2 0 8 49 59 
Hypopharynx 0 0 1 3 4 
Nasopharynx 0 0 0 1 1 
Skull base 0 0 0 1 1 
Unknown primary 0 0 1 8 9 
TOTAL 19 15 22 103 159 
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Table 3. Tumor staging changes made, by tumor site 
 
Tumor Site No Difference 
Stage Difference Percent Staged 
Differently Upstaged Downstaged 
Larynx 19 9 4 41 
Oral cavity  27 18 8 49 
Oropharynx  19 37 3 68 
Hypopharynx 3 1 0 25 
Nasopharynx 0 1 0 100 
Skull base 1 0 0 0 
Unknown primary 5 3 1 44 
TOTAL 74 69 16 53 
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Table 4. Patient characteristics of patients with and without tumor stage change 
Patient Characteristics No Stage 
Difference 
Stage Difference P-
value* Upstaged Downstaged Total 
Sex      0.109 
    Male  53 58 11 69  
    Female 21 11 5 16  
Race     0.42 
European American/White  65 65 15 80  
African American/Black  6 3 0 3  
Asian  1 0 0 0  
American 
Indian/Eskimo/Aleutian  
1 1 1 2  
Other  1 0 0 0  
Baseline tobacco status     0.20 
Never smoker  14 22 4 26  
Current in past 12 mo 39 27 8 35  
Former smoker >12mo  21 20 4 24  
Baseline alcohol status     0.97 
Never drinker  5 6 1 7  
Current drinker  52 45 13 58  
Former drinker >12mo  17 18 2 20  
BMI Category     0.61 
Underweight  7 4 0 4  
Normal  27 26 10 36  
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Overweight  25 23 3 26  
Obese 15 16 3 19  
Recurrence      0.54 
Alive, no recurrence  57 53 12 65  
Recurred or persistence  17 16 4 20  
Disease Persistence      0.57 
No disease present after 
treatment  
65 62 13 75  
Disease present after 
treatment completed or 
palliative at baseline  
9 7 3 10  
Education Level     0.93 
Less than High School  3 2 2 4  
High School or GED  19 11 6 17  
Some College  21 21 3 24  
4 year degree or greater  17 13 3 16  
Marital Status     0.39 
Married  51 46 7 53  
Widowed  5 7 4 11  
Separated or divorced  8 4 1 5  
Never married  9 10 3 13  
*Fisher exact test was conducted for each category comparing the number of patients with no stage 
difference to the total number of patients with a stage difference, either upstaged or downstaged 
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Figure 1. Tumor staging changes made, by tumor site  
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Objective: To characterize the differences in the staging and treatment of patients with head and 
neck squamous cell carcinoma between a tertiary care center and community-based practices. 
Methods: This study is a retrospective chart review of 943 adult patients with head and neck 
squamous cell cancer presenting to a tertiary care center between 2008 and 2014 as part of the 
University of Michigan Head and Neck Cancer Specialized Program of Research Excellence (UM HN-
SPORE) database. Demographic information, diagnostic testing, staging information, and treatment 
recommendations were recorded.  
Results: Of 943 patients reviewed, 159 had documentation of tumor stage that was assigned by the 
community-based practice. Of these, 53% had a tumor staging change made at the tertiary care 
center, with 43% of patients upstaged and 10% of patients downstaged. 51% received different 
treatment than had previously been offered at the community-based practice, although only 31% of 
these patients had a change in tumor staging.  
Conclusion: Over half of patients with head and neck squamous cell carcinoma who are evaluated 
at a tertiary care center after the initial evaluation at a community-based practice have their tumors 
staged differently, with the majority upstaged. A significant number of these patients also received 
different treatment than was initially offered at the referring practice. Future studies are required 
to determine whether these differences have an effect on tumor recurrence and patient survival 
rates.  
 
Key Words: adult head and neck squamous cell carcinoma, neoplasm staging, tertiary care 
center 
 
Level of Evidence: 2c (Outcomes Research) 
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In the assessment of head and neck cancer, accurate staging is imperative because 
prognosis and treatment are directly related to the tumor stage assigned to each patient.1 Tumor 
staging allows meaningful discussion between members of the patient care team to achieve an 
appropriate and customized treatment plan for each patient.2,3 Originating from the American Joint 
Committee on Cancer (AJCC) in conjunction with the International Union Against Cancer (UICC), 
TNM classification of head and neck cancer4 is now the standard staging system used in clinical 
practice and the published literature.1  
Despite the importance of initial staging, relatively few studies have examined differences in 
the staging process or compared tumor stage assignments between institutions. Although studies 
have shown a disparity in survival rates of head and neck cancer patients between different 
institutions, no study has compared tumor staging assignments to identify staging differences and 
restaging between institutions.5,6  
We hypothesized that there are institutional differences in tumor stage assignment. We 
sought to quantify these differences and to identify patient-specific factors associated with these 
differences and secondarily to compare differences in treatment recommendations.  We designed a 
study to compare institutional tumor staging by examining patients diagnosed with head and neck 
squamous cell carcinoma at community-based practices who subsequently presented to our 
tertiary care academic center. We sought to identify whether staging differences identified are a 
result of patient-specific factors, if different treatment was offered at the tertiary care center, and if 
treatment differences were related to staging changes. 
 
Materials and Methods 
A retrospective chart review was conducted on patients within the University of Michigan 
Head and Neck Cancer Specialized Program of Research Excellence (UM HN-SPORE).  The UM HN-
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SPORE database consists of patients who have presented to the University of Michigan for 
evaluation and treatment of head and neck cancers, and consented to be in research studies 
regarding factors impacting treatment and survival of their cancers.  We identified patients who 
had previously been staged at a community-based practice and had subsequently been staged at 
our tertiary care center, the University of Michigan. We included all patients with HNSCC. Upon 
registration into the UM HN-SPORE database, demographic information on each patient had been 
collected along with diagnosis, treatment, and outcome measures. Race was self-reported by 
patients. For the purposes of this study, the data collection also included chart review of referral 
documentation to determine tumor staging by community-based practice, treatment offered by the 
community practice, and whether the patient then presented to the tertiary care center for 
assumption of care versus a second opinion. Descriptive statistics were calculated on 
demographics, changes in staging, reasons for changes in stage, and treatment offered. 
Demographic differences were analyzed between patients with staging changes, compared to those 
with no staging change, using Fisher’s Exact test at a significance level of alpha = 0.05.   Statistical 




In total, 943 patients were reviewed. Of these, 159 patients had complete documentation 
from the community-based practice including tumor staging; this patient subset was the main 
group analyzed. The mean age of these patients was 60 years. 77% of patients were male, 23% 
female, and the vast majority were European American/White (91%) with the remainder including 
6% African American/Black, 1% Asian, 2% American Indian/Eskimo/ Aleutian, and 1% other.   
Wait-time between staging of patient at the community-based practice and initial presentation to 
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the tertiary care center was on average 14.7 days. Complete patient characteristics are 
demonstrated in Table 1. 
Following evaluation at the tertiary care center, 85 (53%) patients were re-assigned a 
different tumor stage, with 69 (43%) patients upstaged and 16 (10%) patients downstaged [Table 
2]. Of the patients with staging changes, 45 (53%) had been evaluated by a multidisciplinary tumor 
board at the tertiary care institute. Of this subset, 24 patients underwent stage change based on the 
tumor board recommendations, with the other 21 patients having had an initial staging that was 
already changed from that given at the referring institute during tertiary care clinic evaluation. 
Patients with HNSCC of the oropharynx and of the tongue were most commonly upstaged compared 
to other tumor sites. Reasons for staging changes included differences in clinical exam at the 
tertiary care center (e.g. lymph node determined to be larger), differences in radiology reviews (e.g. 
an additional enlarged lymph node identified), and new imaging taken. Patient characteristics 
including demographics, disease recurrence, and persistence were compared between those that 
had tumor staging changes made at the tertiary care center and those that did not, revealing that 
tumors of the oropharynx had the highest percentage (68%) of restaging. [Table 3]. Fisher Exact 
testing, between patients with tumor staging change and those without, did not reveal any 
statistically significant differences.  
Treatment offered at the community-based practice was then compared to treatment 
received by the patient at the tertiary care center. Of the 159 patients with outside records 
analyzed, 78 patients had documentation of specific treatment recommendations at the 
community-based practice and treatment received at the tertiary care center. Of these, 37 (47%) 
patients received treatment that was different than what was recommended by the community-
based practice. Interestingly, only 18 of these patients, or roughly half, had staging changes made. 
Thus, 19 patients received treatment that was different than initially recommended by the 
community-based practice even without having undergone a change in tumor staging status. Also of 
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note, of the 37 patients with a treatment change, 20 (54%) had been referred for a second opinion, 
not specifically for assumption of clinical care.  
 
Discussion 
Tumors of the head and neck are expected to be clinically staged under AJCC guidelines,1 
but our data reveals that HNSCC tumors are often staged differently at tertiary care centers 
compared to community-based practices. In patients analyzed in this study, over half of tumors 
were restaged. The majority were restaged with a more advanced stage by the tertiary care center, 
despite relatively minimal time between the referral and tertiary care center evaluation. 
Additionally, many of the patients had a change in treatment received at the tertiary care center 
compared to what was recommended by the community-based practice. Roughly half of these 
patients had their tumor staging changed prior to treatment. The other half did not, meaning the 
change in treatment recommended was due to a factor outside of tumor staging. Details of why 
each patient’s treatment regimen was recommended at the community-based hospital were unable 
to be characterized, though presumably related to evaluation of clinical characteristics and 
imaging/diagnostic studies.  
The differences in tumor staging between community-based practices and tertiary care 
centers may be attributed to overall volume and experience with head and neck cancer, as well as 
the availability of additional specialists including highly trained radiologists and cytopathologists 
available through multidisciplinary tumor boards to clarify clinically challenging cases. Previous 
literature has examined overall differences in survival of head and neck cancer patients at different 
treating institutions.5,6 One such study evaluating patients with local advanced head and neck 
cancer undergoing definitive radiotherapy found that treatment at high-volume facilities and 
academic centers is independently associated with improved survival, using the National Cancer 
Data Base to include over 46,000 patients.7 When determining what led to the difference, studies 
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have implicated factors such as the volume of treatments rendered at the facilities8, technical 
expertise 9 as well as multidisciplinary team management 3,9. In one study examining 1195 
Medicare patients with advanced head and neck cancer treated at high and low volume centers, 
patients were found to have nearly statistically significant better survival at high volume hospitals 
despite no association found in receiving multimodality therapy.10 This implies that survival-
promoting features of high volume hospitals extends beyond guideline adherence. These studies 
overall also imply a difference in overall patient care across institutions and may explain the 
observed negative effect on survival noted on the literature.3,6 Therefore, it is apparent that further 
exploration of the staging process represents a major avenue for identifying factors that affect the 
institutional-based outcome differences.  
 A typical diagnostic work-up to determine staging traditionally involves a thorough history 
and physical examination, followed by additional testing which may include endoscopy of the upper 
aerodigestive tract, imaging via computed tomography (CT), magnetic resonance imaging (MRI), 
ultrasonography (US), fine needle aspiration cytology (FNAC) of a neck mass and incisional biopsy 
of the primary tumor 11-13. While these additional tests can lead to greater accuracy in determining 
disease extent, clinical judgment of the practitioner or general institutional guidelines may 
conclude that additional testing is unnecessary to accurately stage the tumor. Therefore, a wide 
range of test utilization between practitioners and institutions is likely. Recently, Lewis et al have 
analyzed pre-referral staging at community institutions for adherence to the National 
Comprehensive Cancer Network (NCCN) guidelines. Their data showed significant deviation from 
the guidelines by community-based practices, leading to inadequate surgical treatment and 
misdiagnosis for patients treated only at community institutions 14.  
At our tertiary care center, staging is based on NCCN guidelines and is often confirmed or 
augmented via evaluation by a multidisciplinary tumor board. In this dataset, of 159 patients 
identified, 84 (53%) underwent tumor board evaluation. Community-based practices often do not 
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have such easy and coordinated access to specialists of other disciplines which can significantly aid 
in the evaluation of tumors, especially in more complicated cases or areas of tumor that are more 
rare, therefore very infrequently seen in the community. The positive effect of multidisciplinary 
tumor boards in impacting patient assessment and management has been studied in many 
oncological settings, from head and neck cancer to breast, urologic, gastrointestinal, and 
gynecological cancers.15-20 A recent systematic review reporting that between 4% to 45% of 
patients discussed at multidisciplinary team meetings had changes in diagnostic reports.21 
Additionally, the clinical impact of multidisciplinary head and neck tumor board has been 
previously studied, examining discussion of 120 consecutive patients which revealed that 27% of 
patients had some change in tumor diagnosis, stage, or treatment plan.15 Our study has gone a step 
further in directly assessing the referral documentation and work up at community-based 
practices, as well as patient demographic factors. Our findings support the prior study’s conclusion 
that multidisciplinary approaches to patient care affect staging and treatment recommendations. 
Regarding staging, our data reveals that particular tumor sites may lead to increased 
staging discrepancies, as 68% of oropharynx tumors were re-staged at the tertiary care center 
compared to 49% of oral cavity tumors and 41% of larynx tumors. This may relate to the changes in 
oropharynx tumor staging with the important recognition of differences in survival for Human 
Papilloma Virus (HPV)-associated tumors.22 As new staging systems have arisen, academic centers 
may have earlier access to this information and process than community-based centers. 
Additionally, oropharyngeal tumors can be difficult to assess radiologically in regards to 
involvement in extrinsic musculature of the tongue or pterygoids which highly trained radiologists 
can aid with at academic centers particularly through multidisciplinary tumor boards. Community-
based centers may not have the same access. With classification of HPV tumors, cytopathology also 
plays a crucial role. Academic centers may have better access to more specialized cytopathologists 
as well. The interpretation of diagnostic studies is subject to high variability between institutions 
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and between providers, possibly leading to the deviations.  Previous studies have indicated that 
reinterpretation of imaging in the setting of a multidisciplinary cancer center has a significant effect 
on staging, management, and prognosis9,23,24. As our data shows, roughly half of the patients 
evaluated with staging changes had this change made in the context of review by a 
multidisciplinary tumor board.  
There are several limitations of this study. First, the database was limited to patients who 
sought evaluation at a tertiary care center.  This group may inherently be more difficult to examine 
and diagnose, leading to greater discrepancy in staging. Additionally, referral documents used in 
chart review may not have included all outside clinical notes which community-based practices 
may have used to determine tumor stage.  The patient group was fairly diverse with respect to 
tumor site and stage, making it difficult to identify any differences in outcome or whether 
differences in patient characteristics could be confounding. It is also possible that patients may not 
have been clinically understaged, but rather that the disease progressed by the time they were 
referred to our institution. However, given our finding that patients were subsequently evaluated at 
the tertiary care center on average only 14 days after their referral encounter, this is less likely to 
present a significant limitation. Additionally, it could be argued that because this study is limited to 
patients presenting to a tertiary care center, that community-based practices may not have 
conducted additional tests or diagnostic studies out of an assumption that the tertiary care center 
would assume care and give a final stage and recommendation. However, as noted above, among 
the group of patients with changes in treatment recommendations, 54% had presented for a second 
opinion, without which they presumably would have underwent the initial treatment offered by the 
referring institution. Finally, there is an underlying assumption that the tertiary care center was 
fully adherent to NCCN guidelines in staging; this study did not officially validate the tertiary care 
center staging concordance with NCCN guidelines, and discrepancies therefore could exist.  
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Future studies should examine the differences in exactly how community-based practices 
versus tertiary institutions stage patients, specifically focusing on the tests ordered at each 
institution to aid with staging. Ultimately, survival based on the changes in staging and treatment 
modalities offered to patients at different institutions should be examined in order to determine 
overall and disease free survival. 
 
Conclusion  
Over half of patients with HNSCC who present to tertiary care centers from community-
based practices have their tumors’ stage changed, with the majority upstaged. Interestingly, in 
nearly half of patients receiving treatment that is different than was initially recommended at the 
community-based practice; only half of these patients had undergone a tumor staging change. 
Future studies are required to determine whether these differences result in an effect on patient 
outcomes, including recurrence and survival rates. 
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Table 1. Patient Demographics  
 
Patient Characteristics 
Percent of total  
(N = 159) 
Sex  
    Male 77 
    Female 23 
Age (Years) 60 
Race  
European American/White 91 
African American/Black 6 
Asian 1 
American Indian/Eskimo/Aleutian  2 
Other  1 
Baseline tobacco status  
Never smoker  25 
Current in past 12 mo 47 
Former smoker >12mo  28 
Baseline alcohol status  
Never drinker  8 
Current drinker  69 
Former drinker >12mo 23 
BMI Category  
Underweight  7 
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t  328 
 329 
330 
Normal  40 
Overweight  32 
Obese 21 
Recurrence  
Alive, no recurrence 77 
Recurred or persistence  23 
Disease Persistence  
No disease present after treatment  88 
Disease present after treatment 
completed or palliative at baseline  
12 
Education Level (N = 121) 
Less than High School  6 
High School or GED  30 
Some College  37 
4 year degree or greater  27 
Marital Status (N = 155) 
Married  67 
Widowed  10 
Separated or divorced  8 
Never married  14 
Median Household Income ($) 48,202.00 
Average Wait Time 14.7 days  
(Range 0-163 days) 
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Table 2. Patient tumor sites and stages determined by tertiary care center 
 
Tumor Site Stage 1 Stage 2 Stage 3 Stage 4 Total 
Larynx 10 4 4 14 32 
Oral cavity  7 11 8 27 53 
Oropharynx  2 0 8 49 59 
Hypopharynx 0 0 1 3 4 
Nasopharynx 0 0 0 1 1 
Skull base 0 0 0 1 1 
Unknown primary 0 0 1 8 9 
TOTAL 19 15 22 103 159 
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Table 3. Tumor staging changes made, by tumor site 
 
Tumor Site No Difference 
Stage Difference Percent Staged 
Differently Upstaged Downstaged 
Larynx 19 9 4 41 
Oral cavity  27 18 8 49 
Oropharynx  19 37 3 68 
Hypopharynx 3 1 0 25 
Nasopharynx 0 1 0 100 
Skull base 1 0 0 0 
Unknown primary 5 3 1 44 
TOTAL 74 69 16 53 
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Table 4. Patient characteristics of patients with and without tumor stage change 
Patient Characteristics No Stage 
Difference 
Stage Difference P-
value* Upstaged Downstaged Total 
Sex      0.109 
    Male  53 58 11 69  
    Female 21 11 5 16  
Race     0.42 
European American/White  65 65 15 80  
African American/Black  6 3 0 3  
Asian  1 0 0 0  
American 
Indian/Eskimo/Aleutian  
1 1 1 2  
Other  1 0 0 0  
Baseline tobacco status     0.20 
Never smoker  14 22 4 26  
Current in past 12 mo 39 27 8 35  
Former smoker >12mo  21 20 4 24  
Baseline alcohol status     0.97 
Never drinker  5 6 1 7  
Current drinker  52 45 13 58  
Former drinker >12mo  17 18 2 20  
BMI Category     0.61 
Underweight  7 4 0 4  
Normal  27 26 10 36  
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Overweight  25 23 3 26  
Obese 15 16 3 19  
Recurrence      0.54 
Alive, no recurrence  57 53 12 65  
Recurred or persistence  17 16 4 20  
Disease Persistence      0.57 
No disease present after 
treatment  
65 62 13 75  
Disease present after 
treatment completed or 
palliative at baseline  
9 7 3 10  
Education Level     0.93 
Less than High School  3 2 2 4  
High School or GED  19 11 6 17  
Some College  21 21 3 24  
4 year degree or greater  17 13 3 16  
Marital Status     0.39 
Married  51 46 7 53  
Widowed  5 7 4 11  
Separated or divorced  8 4 1 5  
Never married  9 10 3 13  
*Fisher exact test was conducted for each category comparing the number of patients with no stage 
difference to the total number of patients with a stage difference, either upstaged or downstaged 
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